Review




Structured Review

Simcyp piperaquine pbpk model
Overview of the workflow for physiologically‐based pharmacokinetic modeling of <t>piperaquine</t> for a pregnant population using an individualized profile (‘virtual twin’) approach.
Piperaquine Pbpk Model, supplied by Simcyp, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/piperaquine pbpk model/product/Simcyp
Average 86 stars, based on 1 article reviews
piperaquine pbpk model - by Bioz Stars, 2026-06
86/100 stars

Images

1) Product Images from "Physiologically‐Based Pharmacokinetic Modeling to Investigate Piperaquine Exposure in Pregnant Women Using an Individualized Profile Approach"

Article Title: Physiologically‐Based Pharmacokinetic Modeling to Investigate Piperaquine Exposure in Pregnant Women Using an Individualized Profile Approach

Journal: Clinical and Translational Science

doi: 10.1111/cts.70589

Overview of the workflow for physiologically‐based pharmacokinetic modeling of piperaquine for a pregnant population using an individualized profile (‘virtual twin’) approach.
Figure Legend Snippet: Overview of the workflow for physiologically‐based pharmacokinetic modeling of piperaquine for a pregnant population using an individualized profile (‘virtual twin’) approach.

Techniques Used:

Individual piperaquine normalized AUC ratios ( R AUC / Dose ) for the first dose (blue solid line) and last dose (blue dotted line) in (a) Sudanese pregnant women, second trimester; (b) Sudanese pregnant women, third trimester; (c) Thai pregnant women, second trimester; (d) Thai pregnant women, third trimester. Internal gray line: R AUC = 0 , middle gray line: R AUC = 1 , and external gray line: R AUC = 2 . ID, identification number for the women included in the clinical trials. ID = patient identification number.
Figure Legend Snippet: Individual piperaquine normalized AUC ratios ( R AUC / Dose ) for the first dose (blue solid line) and last dose (blue dotted line) in (a) Sudanese pregnant women, second trimester; (b) Sudanese pregnant women, third trimester; (c) Thai pregnant women, second trimester; (d) Thai pregnant women, third trimester. Internal gray line: R AUC = 0 , middle gray line: R AUC = 1 , and external gray line: R AUC = 2 . ID, identification number for the women included in the clinical trials. ID = patient identification number.

Techniques Used: Clinical Proteomics

Mean plasma concentration–time plots for piperaquine in plasma in representative individualized profiles compared to observed data for (a) a Sudanese pregnant woman (second trimester, patient ID7), and (b) a Thai pregnant woman (second trimester, patient ID6). The shaded area is 95% prediction interval.
Figure Legend Snippet: Mean plasma concentration–time plots for piperaquine in plasma in representative individualized profiles compared to observed data for (a) a Sudanese pregnant woman (second trimester, patient ID7), and (b) a Thai pregnant woman (second trimester, patient ID6). The shaded area is 95% prediction interval.

Techniques Used: Clinical Proteomics, Concentration Assay

Predicted vs. observed piperaquine clearance up to Day 7 in (a) Sudanese pregnant women, and (b) Thai pregnant women. The central line is the median, the box represents the interquartile range, the cross is the mean, and the whiskers are the lowest and highest values.
Figure Legend Snippet: Predicted vs. observed piperaquine clearance up to Day 7 in (a) Sudanese pregnant women, and (b) Thai pregnant women. The central line is the median, the box represents the interquartile range, the cross is the mean, and the whiskers are the lowest and highest values.

Techniques Used:

Piperaquine concentrations on Day 7 for (a) individual predicted vs. observed plasma concentrations and predictive performance assessed by (b) prediction error (PE), and (c) relative difference (RD). The central line is the median, the box represents the interquartile range, the cross is the mean, and the whiskers are the lowest and highest values. All the predicted concentrations were normalized by the actual mg/kg dose administered to the patient. T2 = second trimester; T3 = third trimester.
Figure Legend Snippet: Piperaquine concentrations on Day 7 for (a) individual predicted vs. observed plasma concentrations and predictive performance assessed by (b) prediction error (PE), and (c) relative difference (RD). The central line is the median, the box represents the interquartile range, the cross is the mean, and the whiskers are the lowest and highest values. All the predicted concentrations were normalized by the actual mg/kg dose administered to the patient. T2 = second trimester; T3 = third trimester.

Techniques Used: Clinical Proteomics



Similar Products

86
Simcyp piperaquine pbpk model
Overview of the workflow for physiologically‐based pharmacokinetic modeling of <t>piperaquine</t> for a pregnant population using an individualized profile (‘virtual twin’) approach.
Piperaquine Pbpk Model, supplied by Simcyp, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/piperaquine pbpk model/product/Simcyp
Average 86 stars, based on 1 article reviews
piperaquine pbpk model - by Bioz Stars, 2026-06
86/100 stars
  Buy from Supplier

86
Simcyp simcyp pbpk simulator
Overview of the workflow for physiologically‐based pharmacokinetic modeling of <t>piperaquine</t> for a pregnant population using an individualized profile (‘virtual twin’) approach.
Simcyp Pbpk Simulator, supplied by Simcyp, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/simcyp pbpk simulator/product/Simcyp
Average 86 stars, based on 1 article reviews
simcyp pbpk simulator - by Bioz Stars, 2026-06
86/100 stars
  Buy from Supplier

86
Simcyp physiologicallybased pharmacokinetics pbpk modeling platform
Overview of the workflow for physiologically‐based pharmacokinetic modeling of <t>piperaquine</t> for a pregnant population using an individualized profile (‘virtual twin’) approach.
Physiologicallybased Pharmacokinetics Pbpk Modeling Platform, supplied by Simcyp, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/physiologicallybased pharmacokinetics pbpk modeling platform/product/Simcyp
Average 86 stars, based on 1 article reviews
physiologicallybased pharmacokinetics pbpk modeling platform - by Bioz Stars, 2026-06
86/100 stars
  Buy from Supplier

86
Simcyp pbpk framework
Overview of the workflow for physiologically‐based pharmacokinetic modeling of <t>piperaquine</t> for a pregnant population using an individualized profile (‘virtual twin’) approach.
Pbpk Framework, supplied by Simcyp, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/pbpk framework/product/Simcyp
Average 86 stars, based on 1 article reviews
pbpk framework - by Bioz Stars, 2026-06
86/100 stars
  Buy from Supplier

86
Simcyp maternal pbpk model
Overview of the workflow for physiologically‐based pharmacokinetic modeling of <t>piperaquine</t> for a pregnant population using an individualized profile (‘virtual twin’) approach.
Maternal Pbpk Model, supplied by Simcyp, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/maternal pbpk model/product/Simcyp
Average 86 stars, based on 1 article reviews
maternal pbpk model - by Bioz Stars, 2026-06
86/100 stars
  Buy from Supplier

pbpk  (Simcyp)
86
Simcyp pbpk
Overview of the workflow for physiologically‐based pharmacokinetic modeling of <t>piperaquine</t> for a pregnant population using an individualized profile (‘virtual twin’) approach.
Pbpk, supplied by Simcyp, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/pbpk/product/Simcyp
Average 86 stars, based on 1 article reviews
pbpk - by Bioz Stars, 2026-06
86/100 stars
  Buy from Supplier

86
Simcyp maternal fetal pbpk model in simcyp
Overview of the workflow for physiologically‐based pharmacokinetic modeling of <t>piperaquine</t> for a pregnant population using an individualized profile (‘virtual twin’) approach.
Maternal Fetal Pbpk Model In Simcyp, supplied by Simcyp, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/maternal fetal pbpk model in simcyp/product/Simcyp
Average 86 stars, based on 1 article reviews
maternal fetal pbpk model in simcyp - by Bioz Stars, 2026-06
86/100 stars
  Buy from Supplier

86
Simcyp 2013 pbpk model
Overview of the workflow for physiologically‐based pharmacokinetic modeling of <t>piperaquine</t> for a pregnant population using an individualized profile (‘virtual twin’) approach.
2013 Pbpk Model, supplied by Simcyp, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/2013 pbpk model/product/Simcyp
Average 86 stars, based on 1 article reviews
2013 pbpk model - by Bioz Stars, 2026-06
86/100 stars
  Buy from Supplier

Image Search Results


Overview of the workflow for physiologically‐based pharmacokinetic modeling of piperaquine for a pregnant population using an individualized profile (‘virtual twin’) approach.

Journal: Clinical and Translational Science

Article Title: Physiologically‐Based Pharmacokinetic Modeling to Investigate Piperaquine Exposure in Pregnant Women Using an Individualized Profile Approach

doi: 10.1111/cts.70589

Figure Lengend Snippet: Overview of the workflow for physiologically‐based pharmacokinetic modeling of piperaquine for a pregnant population using an individualized profile (‘virtual twin’) approach.

Article Snippet: The piperaquine PBPK model was previously developed and validated within Simcyp for a healthy non‐pregnant population.

Techniques:

Individual piperaquine normalized AUC ratios ( R AUC / Dose ) for the first dose (blue solid line) and last dose (blue dotted line) in (a) Sudanese pregnant women, second trimester; (b) Sudanese pregnant women, third trimester; (c) Thai pregnant women, second trimester; (d) Thai pregnant women, third trimester. Internal gray line: R AUC = 0 , middle gray line: R AUC = 1 , and external gray line: R AUC = 2 . ID, identification number for the women included in the clinical trials. ID = patient identification number.

Journal: Clinical and Translational Science

Article Title: Physiologically‐Based Pharmacokinetic Modeling to Investigate Piperaquine Exposure in Pregnant Women Using an Individualized Profile Approach

doi: 10.1111/cts.70589

Figure Lengend Snippet: Individual piperaquine normalized AUC ratios ( R AUC / Dose ) for the first dose (blue solid line) and last dose (blue dotted line) in (a) Sudanese pregnant women, second trimester; (b) Sudanese pregnant women, third trimester; (c) Thai pregnant women, second trimester; (d) Thai pregnant women, third trimester. Internal gray line: R AUC = 0 , middle gray line: R AUC = 1 , and external gray line: R AUC = 2 . ID, identification number for the women included in the clinical trials. ID = patient identification number.

Article Snippet: The piperaquine PBPK model was previously developed and validated within Simcyp for a healthy non‐pregnant population.

Techniques: Clinical Proteomics

Mean plasma concentration–time plots for piperaquine in plasma in representative individualized profiles compared to observed data for (a) a Sudanese pregnant woman (second trimester, patient ID7), and (b) a Thai pregnant woman (second trimester, patient ID6). The shaded area is 95% prediction interval.

Journal: Clinical and Translational Science

Article Title: Physiologically‐Based Pharmacokinetic Modeling to Investigate Piperaquine Exposure in Pregnant Women Using an Individualized Profile Approach

doi: 10.1111/cts.70589

Figure Lengend Snippet: Mean plasma concentration–time plots for piperaquine in plasma in representative individualized profiles compared to observed data for (a) a Sudanese pregnant woman (second trimester, patient ID7), and (b) a Thai pregnant woman (second trimester, patient ID6). The shaded area is 95% prediction interval.

Article Snippet: The piperaquine PBPK model was previously developed and validated within Simcyp for a healthy non‐pregnant population.

Techniques: Clinical Proteomics, Concentration Assay

Predicted vs. observed piperaquine clearance up to Day 7 in (a) Sudanese pregnant women, and (b) Thai pregnant women. The central line is the median, the box represents the interquartile range, the cross is the mean, and the whiskers are the lowest and highest values.

Journal: Clinical and Translational Science

Article Title: Physiologically‐Based Pharmacokinetic Modeling to Investigate Piperaquine Exposure in Pregnant Women Using an Individualized Profile Approach

doi: 10.1111/cts.70589

Figure Lengend Snippet: Predicted vs. observed piperaquine clearance up to Day 7 in (a) Sudanese pregnant women, and (b) Thai pregnant women. The central line is the median, the box represents the interquartile range, the cross is the mean, and the whiskers are the lowest and highest values.

Article Snippet: The piperaquine PBPK model was previously developed and validated within Simcyp for a healthy non‐pregnant population.

Techniques:

Piperaquine concentrations on Day 7 for (a) individual predicted vs. observed plasma concentrations and predictive performance assessed by (b) prediction error (PE), and (c) relative difference (RD). The central line is the median, the box represents the interquartile range, the cross is the mean, and the whiskers are the lowest and highest values. All the predicted concentrations were normalized by the actual mg/kg dose administered to the patient. T2 = second trimester; T3 = third trimester.

Journal: Clinical and Translational Science

Article Title: Physiologically‐Based Pharmacokinetic Modeling to Investigate Piperaquine Exposure in Pregnant Women Using an Individualized Profile Approach

doi: 10.1111/cts.70589

Figure Lengend Snippet: Piperaquine concentrations on Day 7 for (a) individual predicted vs. observed plasma concentrations and predictive performance assessed by (b) prediction error (PE), and (c) relative difference (RD). The central line is the median, the box represents the interquartile range, the cross is the mean, and the whiskers are the lowest and highest values. All the predicted concentrations were normalized by the actual mg/kg dose administered to the patient. T2 = second trimester; T3 = third trimester.

Article Snippet: The piperaquine PBPK model was previously developed and validated within Simcyp for a healthy non‐pregnant population.

Techniques: Clinical Proteomics